CN105310075A - Preparation method of natto red yeast rice health care food for assisting in lowering blood lipid - Google Patents
Preparation method of natto red yeast rice health care food for assisting in lowering blood lipid Download PDFInfo
- Publication number
- CN105310075A CN105310075A CN201510613556.2A CN201510613556A CN105310075A CN 105310075 A CN105310075 A CN 105310075A CN 201510613556 A CN201510613556 A CN 201510613556A CN 105310075 A CN105310075 A CN 105310075A
- Authority
- CN
- China
- Prior art keywords
- natto
- red
- making method
- yeast rice
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013557 nattō Nutrition 0.000 title claims abstract description 55
- 235000013305 food Nutrition 0.000 title claims abstract description 30
- 230000036541 health Effects 0.000 title claims abstract description 21
- 229940026314 red yeast rice Drugs 0.000 title claims abstract description 21
- 210000004369 blood Anatomy 0.000 title abstract description 24
- 239000008280 blood Substances 0.000 title abstract description 24
- 150000002632 lipids Chemical class 0.000 title abstract description 10
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 239000000284 extract Substances 0.000 claims abstract description 31
- 239000000843 powder Substances 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 17
- 244000063299 Bacillus subtilis Species 0.000 claims abstract description 14
- 235000014469 Bacillus subtilis Nutrition 0.000 claims abstract description 14
- 244000068988 Glycine max Species 0.000 claims abstract description 14
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 239000002775 capsule Substances 0.000 claims abstract description 10
- 239000008187 granular material Substances 0.000 claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 238000004040 coloring Methods 0.000 claims description 20
- 240000007594 Oryza sativa Species 0.000 claims description 17
- 235000007164 Oryza sativa Nutrition 0.000 claims description 17
- 235000007189 Oryza longistaminata Nutrition 0.000 claims description 12
- 238000009835 boiling Methods 0.000 claims description 12
- 238000005057 refrigeration Methods 0.000 claims description 12
- 238000000855 fermentation Methods 0.000 claims description 10
- 230000004151 fermentation Effects 0.000 claims description 10
- 238000010298 pulverizing process Methods 0.000 claims description 9
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 6
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 238000011081 inoculation Methods 0.000 claims description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000007654 immersion Methods 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 13
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 3
- 210000001367 artery Anatomy 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 4
- 235000019359 magnesium stearate Nutrition 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 26
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 25
- 239000003814 drug Substances 0.000 description 21
- 230000008859 change Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 11
- 150000003626 triacylglycerols Chemical class 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 9
- 235000013402 health food Nutrition 0.000 description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 9
- 244000131316 Panax pseudoginseng Species 0.000 description 7
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 230000002402 anti-lipaemic effect Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 235000009566 rice Nutrition 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 208000032928 Dyslipidaemia Diseases 0.000 description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229940116269 uric acid Drugs 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000002562 urinalysis Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010042434 Sudden death Diseases 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000035614 depigmentation Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940086319 nattokinase Drugs 0.000 description 2
- 108010073682 nattokinase Proteins 0.000 description 2
- 238000005453 pelletization Methods 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 235000020985 whole grains Nutrition 0.000 description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- PFRQBZFETXBLTP-RCIYGOBDSA-N 2-[(2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl]-3-methyl-1,4-dihydronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-RCIYGOBDSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010062714 Dysglobulinaemia Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 1
- 241000031003 Monascus ruber Species 0.000 description 1
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 240000007509 Phytolacca dioica Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940097479 colestid Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002394 glycogenic effect Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- GACQNVJDWUAPFY-UHFFFAOYSA-N n'-[2-[2-(2-aminoethylamino)ethylamino]ethyl]ethane-1,2-diamine;hydrochloride Chemical compound Cl.NCCNCCNCCNCCN GACQNVJDWUAPFY-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000008802 xuezhikang Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a preparation method of natto red yeast rice health care food for assisting in lowering blood lipid. The preparation method is characterized in that soybeans serves as the raw material and is soaked, steamed and boiled, cooled, inoculated with bacillus natto, fermented, refrigerated, frozen, dried, crushed and processed into natto powder, then red yeast rice extract and magnesium stearate are added, then the ingredients are mixed to be prepared into granules or capsules, and the natto red yeast rice health care food is prepared from, by weight, 50-70% of the natto powder, 30-50 parts of the red yeast rice extract and 0-3% of magnesium stearate. According to the preparation method, adopted raw material components are scientific in compatibility, the adopted technological process and method are reasonable, scientific and easy to operate, the obtained product is free of toxic and side effects, capable of being easily absorbed by a human body and convenient to eat, it is beneficial to prevent and control atherosclerosis hardening of the arteries and lower the risk of cardiovascular diseases, and the health care function of assisting in lowering blood lipid is achieved.
Description
Technical field
The present invention relates to a kind of natto health red rice food making method of auxiliary lipid-lowering function, particularly a kind of health food preparation method with auxiliary lipid-lowering function that is raw material with natto, red yeast rice.
Background technology
According to statistics, the annual newly-increased hyperlipemic patients about 5,000,000 in the whole world, about 6,000,000 people therefore disablement and viability, China more than 18 years old dyslipidemia crowd is up to 1.6 hundred million, 1 people is just had to suffer from dyslipidemia in approximately every 10 people, in the crowd in 35-64 year, illness rate reaches 42.9%, wherein, has 2,500 ten thousand people to suffer from hypertension and hyperlipidemia simultaneously.In recent years, the morbidity of hyperlipemia more has rejuvenation trend, and the danger of dyslipidemia to compatriots' health rises to original 3-5 doubly.
Blood fat is the general name of contained lipid in human plasma, comprising cholesterol, triglyceride, cholesterol ester, beta lipoprotein, phosphatide, not esterified resin acid etc.When serum cholesterol exceedes normal value 230mg/100ml, triglyceride, more than 140mg/100ml, when beta lipoprotein is more than more than 390mg/100ml, can be referred to as hyperlipemia.The traditional Chinese medical science is thought, the Etiological of hyperlipemia can be summarized as two and select: one is diet delicious food savoury, impairing the spleen and stomach, and meanwhile, suffocating of liver and gall function is unfluent, semen deposition juice can not be secreted and cause spleen the paddy that disappears, transportation capabilities imbalance, be converted into phlegm turbid; Two is kidney qi degradations after the middle age, and the deficiency in both YIN and YANG of kidney, liver-kidney irritation, causes liver-yang hyperactivity, very then changes fire, and wood is prosperous, takes advantage of soil, makes the defeated cloth functional disturbance of taste, damp and hot pent-up, the turbid interior life of phlegm.Doctor trained in Western medicine is then thought, the cause of disease of high fat of blood can be divided into two large classes substantially: one is essential hyperlipidemia, namely by lipid and lipoprotein metabolism birth defects (familial) and some environmental factor (diet and medicine etc.) by caused by various mechanism; Two is Secondary cases highs fat of blood, is the disease caused by other primary diseases (diabetes, hepatopathy, thyroid disease, kidney trouble, pancreas, obesity, glycogenic thesaurismosis, gout, Addision's disease, Cushing's syndrome and dysglobulinemia etc.).Hyperlipemia morbidity is hidden, mostly without clinical symptoms, therefore is called " stealthy killer "; Atherosclerotic caused by it causes the main cause of coronary heart disease (comprising miocardial infarction, angina pectoris and sudden death), cerebral infarction and peripheral vessels thrombotic disease, the incidence of disease of these cardiovascular and cerebrovascular diseases is high, harm is large, disease progression is dangerous, and the whole world about has 1,200 ten thousand people to die from angiocardiopathy and headstroke every year.
Along with growth in the living standard, in people's meals, fat intake is in increase, and in some crowds, fatty energy supply has exceeded 30% of gross energy.Current China high fat diet has been the obvious hazards of hyperlipidemia.A large amount of investigation and research show, hyperlipidemia is the key factor threatening human health, now thinks that adjustment serum lipid level can reduce the incidence of incidence of coronary heart disease and ischemic heart event (heart stalk, sudden death, unstable angina etc.).Therefore, carry out adjusting blood lipid to prevent the disease caused by hyperlipidemia by natural food, oneself becomes one of focus of current healthcare research.At present, the medicine with hypolipemic function is a lot, and be broadly divided into three classes: a class is the medicine of main norcholesterol, conventional has cholestyramine, Colestid and probacol etc.; One class is that main norcholesterol is held concurrently the medicine of triglyceride reducing, and representative drugs has Lovastatin, Simvastatin and Effects of Xuezhikang etc.; A class is also had to be that main triglyceride reducing is held concurrently the medicine of norcholesterol, with nicotinic acid, CLOF and Bezafibrate etc. for representative.But research finds, these medicines are not overall safeties, have certain side effect, and long-term taking can cause certain harm to health.Therefore, exploitation a kind of energy auxiliary antilipemic is badly in need of and the health food preparation method had no side effect.
Summary of the invention
In order to develop a kind of auxiliary antilipemic and the health food had no side effect, the invention provides a kind of health food preparation method being raw material with soya bean, red yeast rice.
Technical scheme of the present invention is as follows:
A kind of natto health red rice food making method of auxiliary antilipemic, it is characterized in that taking soya bean as raw material, soaked, boiling, cooling, inoculation Bacillus natto, fermentation, refrigeration, freeze drying, pulverizing made natto powder, add red yeast rice extract, dolomol again, through being mixed and made into granule or capsule etc., the percentage by weight of its component is: natto powder 50-70%, red yeast rice extract 30-50%, dolomol 0-3%.
Described immersion is soaked at the temperature of soya bean use water more than 30 DEG C 4 hours;
Described boiling is boiling 20-60 minute at the temperature more than 100 DEG C, steams the degree of crumbing with hand to soybean;
Described cooling be by boiling after ripe beans be cooled to 20-40 DEG C;
When described inoculation Bacillus natto is by ripe beans cooling; Evenly spray into Bacillus natto liquid;
Described fermentation is at temperature 35-45 DEG C, relative humidity 50-90% condition bottom fermentation cultivation 18-30 hour, can produce the natto of more transparent haircuts when fermenting;
Described refrigeration is placed in refrigeration more than 24 hours in 0-10 DEG C of refrigerating chamber by fermenting the natto producing more transparent haircuts;
Described freeze drying, pulverize be by refrigeration after natto make 80-100 object natto pulvis.
Described red yeast rice extract adds Notogineng Extract by the Hongqu powder (red colouring agent) of red yeast rice through pulverizing processing to be mixed, and the percentage by weight of its component is: Hongqu powder (red colouring agent) 70-90%, Notogineng Extract 10-30%.
The extraction process step of described Notogineng Extract is: pseudo-ginseng → pre-treatment → alcohol reflux extracts → merge extract → concentrated → dry → pulverize and sieve → packaging → finished product.
Described granule or capsule are the formulations of health food of the present invention.
Drug introduction of the present invention and drug action mechanism as follows:
Natto in instant component, be that soya bean forms through fermenting bacillus natto, the protein of soybean has indissolubility, and after making natto, become solvable and produce amino acid, and in raw material, non-existent various ferment can produce due to Bacillus natto and association bacterium, helps gastrointestinal disturbances to absorb.The natto powder that the present invention makes has following characteristics: color and luster: pale yellow powder, without caking, without mildew phenomena taste, smell: there is the distinctive fragrance of natto, flavour, free from extraneous odour impurity: without the visible exogenous impurity amino-acid nitrogen of naked eyes: >=0.8% Nattokinase: >=1500Fu/g bafillus natto: >=300 hundred million/g moisture :≤9%.
The health care of natto is main factor-related with the several functions such as Nattokinase wherein, natto isoflavones, soap blue or green element, farnoquinone.Be rich in the blue or green element of soap in natto, can improve constipation, reduce blood fat, prevention colorectal cancer, reduction cholesterol, softening blood vessel, preventing hypertension and artery sclerosis, suppress the functions such as AIDS virus; Containing free isoflavone like substance and the multiple enzyme useful to human body in natto; as superoxide dismutase, catalase, protease, amylase, lipase etc.; they can carcinogen in purged body, improve memory, protect that liver is improved looks, delaying senility etc. has positive effect, and the digestibility of food can be improved; Take in live Bacillus natto can regulating intestinal canal colony balance, prevention dysentery, enteritis and constipation, its effect is better than now conventional lactobacillus micro-ecological preparation in some aspects; The stickum that natto fermentation produces, on coating gastrointestinal tract mucous surface, thus can protect stomach and intestine, can alleviate drunk effect when drinking.
Red colouring agent for food, also used as a Chinese medicine in instant component, energy comprehensive adjustment blood fat, realizes " three fall one liter "; namely reduce cholesterol, triglyceride, low-density lipoprotein, increasing high density lipoprotein, remove blood vessel rubbish; protection blood vessel endothelium, primary prevention and all kinds of cardiovascular and cerebrovascular disease of secondary prevention.
Pseudo-ginseng main product in instant component in the ground such as Yunnan, Guangxi, wild or cultivation.It is warm in nature, and taste is sweet, micro-hardship, returns liver, stomach, large intestine channel, has the function of " strengthening by means of tonics, hemostasia and dissipation blood stasis, swelling and pain relieving ".Pseudo-ginseng contains number of chemical composition, wherein arasaponin is one of principle active component, be separated from the variant growth site of pseudo-ginseng at present and identified 20 various of monomer saponin components, pseudo-ginseng, also containing the medicinal ingredient such as dencichine, flavones, volatile oil, amino acid, phytosterol, carbohydrate, inorganic salts, inorganic ions, has and improves myocardial ischemia, reducing blood lipid, hypotensive, develop immunitypty and hepatic cholagogic effect.Bibliographical information, Notogineng Extract has significant preventive and therapeutic action to the exogenous hyperlipidemia of rat in animal experiment.
Red yeast rice extract in instant component adds Notogineng Extract by the Hongqu powder (red colouring agent) of red yeast rice through pulverizing processing to be mixed, its red yeast rice forms by monascus ruber (Monascus) cultivation and fermentation in general rice, Hongqu powder (red colouring agent) is pulverized by red yeast rice to form, there is nontoxic, safe advantage, and also have reinforcing spleen to promote digestion, effect promoting blood circulation and removing blood stasis, Notogineng Extract has obvious pharmacological action to cardiovascular system, can reduce cholesterol preferably, comprehensive adjustment blood lipid metabolism.
Raw material components compatibility science of the present invention, the processing step adopted and method rationally, science, be easy to operate, the product made has no side effect, be easy to absorption of human body, instant, effective.
Health-care food for assisting blood fat lowering provided by the invention is conducive to the atherosis generation for the treatment of of vascular and reduces the risk of angiocardiopathy, natto red colouring agent for food, also used as a Chinese medicine and the active component reasonable employment of " three is high " will be improved, make that each active ingredient complements each other, reasonable compatibility, well serve the health care of auxiliary antilipemic, aided blood pressure-lowering and auxiliary hyperglycemic, middle and old age hypertension, high fat of blood, the desirable health food of hyperglycemia population.
Detailed description of the invention
Below in conjunction with embodiment, the invention will be further described:
Embodiment 1:
Gathering and selecting soya bean is raw material, with the water soaking 4 hours of more than 30 DEG C temperature, then boiling 50 minutes at the temperature more than 100 DEG C, steam the degree of crumbing with hand to soybean, again the ripe beans after boiling are cooled to 30 DEG C, Bacillus natto liquid is evenly sprayed into when being cooled, 20 hours are cultivated at temperature 37 DEG C, relative humidity 80% condition bottom fermentation after inoculation Bacillus natto, refrigeration more than 20 hours in 10 DEG C of refrigerating chambers is placed in again by fermenting the natto producing more transparent haircuts, again 70 kilograms, 90 object natto pulvis is made in the natto freeze drying after refrigeration, pulverizing, for subsequent use;
Gather and take red yeast rice raw material, through pulverizing the Hongqu powder (red colouring agent) 20 kilograms be processed into; Take pseudo-ginseng raw material, extract through pre-treatment, alcohol reflux, merge extract, concentrated, dry, pulverize and sieve and make Notogineng Extract 7 kilograms; By made Hongqu powder (red colouring agent) 20 kilograms, add Notogineng Extract 0.7 kilogram mixing red colouring agent for food, also used as a Chinese medicine rice extracts 27 kilograms, for subsequent use;
By 7 kilograms, natto pulvis, bent rice extracts 27 kilograms mixing, is processed into granule by mixed material pelletization, drying, whole grain, makes invention formulation through packaging, irradiation sterilization.
Embodiment 2:
Gathering and selecting soya bean is raw material, with the water soaking 4 hours of more than 30 DEG C temperature, then boiling 60 minutes at the temperature more than 100 DEG C, steam the degree of crumbing with hand to soybean, again the ripe beans after boiling are cooled to 20 DEG C, Bacillus natto liquid is evenly sprayed into when being cooled, 30 hours are cultivated at temperature 35 DEG C, relative humidity 80% condition bottom fermentation after inoculation Bacillus natto, refrigeration more than 21 hours in 10 DEG C of refrigerating chambers is placed in again by fermenting the natto producing more transparent haircuts, again 14 kilograms, 80 object natto pulvis is made in the natto freeze drying after refrigeration, pulverizing, for subsequent use;
Gather and take red yeast rice raw material, through pulverizing the Hongqu powder (red colouring agent) 4 kilograms be processed into; Take pseudo-ginseng raw material, extract through pre-treatment, alcohol reflux, merge extract, concentrated, dry, pulverize and sieve and make Notogineng Extract 1.4 kilograms; By made Hongqu powder (red colouring agent) 4 kilograms, add Notogineng Extract 1.4 kilograms mixing red colouring agent for food, also used as a Chinese medicine rice extracts 5.4 kilograms, for subsequent use;
By 14 kilograms, natto pulvis, bent rice extracts 5.4 kilograms mixing, by mixed material pelletization, drying, whole grain, in dried particles, add dolomol 0.6 kilogram again, mix, then incapsulate, polishing, packaging, irradiation sterilization make invention formulation.
Embodiment 3
Set forth the beneficial effect of product of the present invention below by way of function test further, carry out according to the evaluation test method in " health food inspection and assessment technical specification ".
The natto red colouring agent for food, also used as a Chinese medicine capsule auxiliary lipid-lowering function human experiment laboratory report that the present inventor provides is as follows:
1 materials and methods
1.1 sample
Natto red colouring agent for food, also used as a Chinese medicine capsule No.1, No. 2 provide by the present inventor, both outward appearances, taste are substantially identical, and one of them is natto red colouring agent for food, also used as a Chinese medicine capsule of the present invention, and another is placebo.Human oral's RD is every day 2 times, each 3.
1.2 experimenters select
1.2.1 inclusive criteria: experimenter's male or female, age 18-65 year.Blood sampling twice in half a year, twice serum total cholesterol all >=5.2mmol/l or serum triglyceride >=1.65mmol/l, simple dyslipidemia, without obvious brain, the heart, liver, lung, kidney, Hematological Diseases, without Long-term taking medicine history, voluntary tested guarantee cooperation.
1.2.2 Subject Exclusion Criteria: gestation or women breast-feeding their children, to health food allergy sufferers; Merge intentionally, liver, the serious disease patient such as kidney and hemopoietic system; Take the article relevant with tested function in a short time, have influence on result judgement person; Do not meet inclusive criteria, not by the edible given the test agent of regulation, effect or data not umbra sound effect or security judgement person cannot be judged.
1.3 experimental designs and grouping
Adopt two kinds of control design between self and group.Be divided into natto red colouring agent for food, also used as a Chinese medicine capsule test-meal of the present invention to combine placebo group at random by experimenter's blood lipid level, consider that the principal element affecting result is as age, sex, diet etc. as far as possible, carry out harmony inspection, to ensure the comparativity between group.Test-meal experiment is carried out by double-blind study.
1.4 experimental technique
Experimenter takes sample by RD, takes 45 days continuously.Duration of test does not change original eating habit, normal diet.
2 observation index
Every observation index in test-meal on-test and at the end of each to measure once.
2.1 safety indexes
2.1.1 general physical examination: inquire in detail before test and understand the situation such as spirit, sleep, diet, stool and urine of experimenter, body weight, blood pressure, changes in heart rate before and after testing experiment.
2.1.2 routine blood test: red blood cell count(RBC), white blood cell count(WBC) and classification, content of hemoglobin mensuration etc.
2.1.3 routine urinalysis: pH value, leucocyte, glucose in urine etc.
2.1.4 stool routine examination.
2.1.5 Abdominal B type ultrasonography, electrocardiogram, x-ray fluoroscopy of chest check (measuring once before on-test).
2.1.6 blood biochemistry index inspection: the mensuration such as total serum protein (TP), albumin (ALB), glutamic-pyruvic transaminase (ALT), glutamic-oxalacetic transaminease (AST), uric acid (UA), urea nitrogen (BUN), creatinine (Cr), blood sugar (GLU).
2.1.7 bad reaction is observed.
2.2 efficacy measures: serum total cholesterol (CHOL), triglycerides (TG), HDL-C (HDL-C).
3. result judges
3.1CHOL reduces > 10%; TG reduces > 15%; HDL-C rising > 0.104mmol/L; Self compare before and after each functional observation index Test and more all have statistical significance between group after test-meal, can judge that this index is positive;
3.2 serum total cholesterols, triglyceride binomial index are positive, and HDL-C, not significantly lower than control group, can judge that given the test agent has auxiliary lipid-lowering function effect; A positive in serum total cholesterol, triglyceride binomial index, HDL-C, not significantly lower than control group, can judge that given the test agent has auxiliary reduction serum total cholesterol or the effect of auxiliary reduction triglyceride.
4. statistical procedures
Result mean standard deviation represents, self pair data adopts paired t-test, between test group and control group under the neat prerequisite of variance, mean compares employing independent samples t-test, otherwise carries out variables transformations, meets variance and adopts t inspection afterwards together, if variance is still uneven, adopt rank test.
5 results
Double-blind study observation end is made known: take No. 2 persons for placebo, takes No. 1 person for natto red colouring agent for food, also used as a Chinese medicine capsule of the present invention.
5.1 safety observations
5.1.1 ordinary circumstance: test-meal group 52 example, control group 52 example.Before and after test-meal, experimenter's deep love, sleep, diet, stool and urine situation no abnormality seen: control group: male/female is 28/24, the age is 58.04 ± 6.22 years old; Test-meal group, male/female is 27/25, and the age is 58.29 ± 5.33 years old.
5.1.2 Abdominal B type ultrasonography, electrocardiogram, x-ray fluoroscopy of chest detect; All in normal range (NR).
5.1.3 body weight, blood pressure, heart rate, routine urinalysis, stool routine examination, routine blood test are situation of change
Show no obvious abnormalities change in table 1. test-meal sample forward and backward examination trencherman's group and control group body weight, blood pressure, heart rate, routine urinalysis, stool routine examination and routine blood test are all in normal range (NR).
Situation of change (`x ± s) before and after table 1 test-meal test
5.1.4 blood biochemistry index situation of change before and after test-meal test
In the forward and backward test-meal group of table 2 test-meal sample and control group total serum protein (TP), albumin (ALB), paddy third turn of ammonia (ALT), glutamic-oxalacetic transaminease (AST), creatinine (Cr), blood sugar (GLU), uric acid (UA), urea nitrogen (BUN) all in normal range (NR).
Blood biochemistry index situation of change (`x ± s) before and after table 2 test-meal test
5.1.5 obvious adverse reaction is had no during test-meal.
5.2 functional observation
In table 3,4,5.Blood sampling twice in half a year, 2 blood fat data before being respectively test-meal and before test-meal, carry out dividing into groups and statistical disposition with date 2 blood lipid levels before the test-meal of taking given the test agent.Before test, control group and test-meal group change of serum C HOL, TG level compare, no significant difference (P<0.05), point out between two groups and there is comparativity, after test-meal group, CHOL, TG compare with before test-meal and after control group test-meal, and difference all has conspicuousness (P<0.05).Before and after test-meal, HDOL_C level has no obvious change (P<0.05).
Change of serum C HOL, TG, HDL_C level (`x ± s) before table 3 test-meal test
Change of serum C HOL, TG, HDOL_C level (`x ± s) before and after table 4 test-meal test
Note: * with compare P<0.05# before test-meal and compare P<0.05 with control group
Change of serum C HOL, TG, HDOL_C situation of change before and after table 5 test-meal test
5..3 depigmentation rate
After test in 45 days, control group has 1 routine experimenter cannot judge that effect is screened out because being interrupted to take by test product; Examination group has 1 routine experimenter cannot judge that effect is screened out because being interrupted to take by test product.Last efficiency test crowd control group 51 example, test-meal group 51 groups.In table 6
Depigmentation rate tested by table 6
6, brief summary
Adopt counter point between own control and group; the volunteer meeting experimental condition is selected to take tested material after 45 days; result shows: take natto red colouring agent for food, also used as a Chinese medicine capsule test group of the present invention food rear CHOL, TG and decline 10.79%, 16.92% before test-meal more respectively; compare before test-meal group CHOL, TG test-meal and after control group test-meal after test-meal, difference all has conspicuousness (P<0.05); After test-meal, test-meal group HDL_C and control group comparing difference are without conspicuousness (P > 0.05).Obvious adverse reaction is had no during test-meal.According to " health food is tested and assessment technique specification " evaluation criterion, prompting given the test agent has auxiliary lipid-lowering function effect.
Claims (9)
1. the natto health red rice food making method of an auxiliary lipid-lowering function, it is characterized in that taking soya bean as raw material, soaked, boiling, cooling, inoculation Bacillus natto, fermentation, refrigeration, freeze drying, pulverizing be processed into natto powder, add red yeast rice extract, dolomol again, then through being mixed and made into granule or capsule etc., the percentage by weight of its component is: natto powder 50-70%, red yeast rice extract 30-50%, dolomol 0-3%.
2. the natto health red rice food making method of a kind of auxiliary lipid-lowering function according to claim 1, is characterized in that described immersion is soaked at the temperature of soya bean use water more than 30 DEG C 4 hours.
3. the natto health red rice food making method of a kind of auxiliary lipid-lowering function according to claim 1, is characterized in that described boiling is boiling 20-60 minute at temperature more than 100 DEG C, steams the degree of crumbing with hand to soybean.
4. the natto health red rice food making method of a kind of auxiliary lipid-lowering function according to claim 1, it is characterized in that described cooling be by boiling after ripe beans be cooled to 20-40 DEG C.
5. the natto health red rice food making method of a kind of auxiliary lipid-lowering function according to claim 1, when is characterized in that described inoculation Bacillus natto is by ripe beans cooling; Evenly spray into Bacillus natto liquid.
6. the natto health red rice food making method of a kind of auxiliary lipid-lowering function according to claim 1, it is characterized in that described fermentation is at temperature 35-45 DEG C, relative humidity 50-90% condition bottom fermentation cultivation 18-30 hour, the natto of more transparent haircuts when fermenting, can be produced.
7. the natto health red rice food making method of a kind of auxiliary lipid-lowering function according to claim 1, is characterized in that described refrigeration is placed in refrigeration more than 24 hours in 0-10 DEG C of refrigerating chamber by fermenting the natto producing more transparent haircuts.
8. the natto health red rice food making method of a kind of auxiliary lipid-lowering function according to claim 1, it is characterized in that described freeze drying, pulverize be by refrigeration after natto make 80-100 object natto pulvis.
9. the natto health red rice food making method of a kind of auxiliary lipid-lowering function according to claim 1, it is characterized in that described red yeast rice extract adds Notogineng Extract by the Hongqu powder (red colouring agent) of red yeast rice through pulverizing processing to be mixed, the percentage by weight of its component is: Hongqu powder (red colouring agent) 70-90%, Notogineng Extract 10-30%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510613556.2A CN105310075A (en) | 2015-09-23 | 2015-09-23 | Preparation method of natto red yeast rice health care food for assisting in lowering blood lipid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510613556.2A CN105310075A (en) | 2015-09-23 | 2015-09-23 | Preparation method of natto red yeast rice health care food for assisting in lowering blood lipid |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105310075A true CN105310075A (en) | 2016-02-10 |
Family
ID=55239169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510613556.2A Pending CN105310075A (en) | 2015-09-23 | 2015-09-23 | Preparation method of natto red yeast rice health care food for assisting in lowering blood lipid |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105310075A (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105661335A (en) * | 2016-02-25 | 2016-06-15 | 贵州秀生堂医药生物有限公司 | Preparation method of natto enteric capsule functional food |
CN106376926A (en) * | 2016-08-31 | 2017-02-08 | 成都润馨堂药业有限公司 | Formula and preparation method of hard capsule with assisted blood fat reducing function |
CN106616367A (en) * | 2016-09-12 | 2017-05-10 | 福建农林大学 | Method for preparing blood-lipid-reducing vinegar beans through coupling of soybean endogenous enzyme bioconversion and acidolysis |
CN106616284A (en) * | 2016-12-29 | 2017-05-10 | 恩施市大集焦氏米业有限责任公司 | Selenium-enriched nutritious rice flour with auxiliary blood-lipid reducing effect and preparation method thereof |
CN106798252A (en) * | 2017-01-20 | 2017-06-06 | 武汉虹辰远荣生物制品有限公司 | A kind of natto prescription with coordinating intestines and stomach reducing blood lipid thrombus dissolving effect |
CN106954798A (en) * | 2017-03-11 | 2017-07-18 | 北京中科卓尔生物科技有限公司 | Red yeast rice natto fine powder and preparation method thereof |
CN107087739A (en) * | 2017-05-26 | 2017-08-25 | 西宝生物科技(上海)股份有限公司 | Solid beverage formula for improving turbid phlegm and blood stasis |
CN107343605A (en) * | 2017-05-15 | 2017-11-14 | 蚌埠市星光豆制品厂 | A kind of instant natto of flavor |
CN107751801A (en) * | 2017-10-19 | 2018-03-06 | 长沙爱扬医药科技有限公司 | The natto product of prevention of cardiovascular disease |
CN108771248A (en) * | 2018-05-17 | 2018-11-09 | 吉林修正健康股份有限公司 | A kind of health-care food for assisting blood fat lowering full of nutrition and preparation method thereof |
CN108991358A (en) * | 2018-07-24 | 2018-12-14 | 山东海钰生物股份有限公司 | A kind of auxiliary reducing blood lipid, it is hypoglycemic, alleviate gout health care food and production method |
WO2019024016A1 (en) * | 2017-08-02 | 2019-02-07 | 江苏安惠生物科技有限公司 | Immunity-enhancing capsule |
CN109589356A (en) * | 2018-11-29 | 2019-04-09 | 天津市农业生物技术研究中心 | A kind of cassia seed composition with auxiliary lipid-lowering efficacy |
CN109602023A (en) * | 2019-01-21 | 2019-04-12 | 因皇生物科技有限公司 | A kind of functional food and preparation method thereof assisting reducing blood lipid using soybean as primary raw material |
CN110859869A (en) * | 2019-12-20 | 2020-03-06 | 中国中医科学院中医药科技合作中心 | A composition for preventing and treating cardiovascular and cerebrovascular diseases, and its preparation method |
CN111700271A (en) * | 2020-07-02 | 2020-09-25 | 山东花为酶生物科技有限公司 | Preparation method of functional food for regulating blood fat, removing freckles and reducing blood viscosity |
CN112999261A (en) * | 2021-03-22 | 2021-06-22 | 天津市宝恒生物科技有限公司 | Natto fermented composition capable of relieving arteriosclerosis and preparation method and application thereof |
CN115299596A (en) * | 2021-11-10 | 2022-11-08 | 山东安然纳米实业发展有限公司 | Ginseng stem cell-containing composition for assisting in reducing blood fat and application thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1714675A (en) * | 2005-07-26 | 2006-01-04 | 李英姬 | Natto powder and preparing method and health food containing such natto powder |
CN101664184A (en) * | 2009-09-22 | 2010-03-10 | 黑龙江省祖研北药科技开发有限责任公司 | Healthcare product for reducing blood fat and preparation method thereof |
CN102600227A (en) * | 2012-03-05 | 2012-07-25 | 吴江谷力生物科技有限公司 | Compound functional red rice capsule |
CN102885306A (en) * | 2012-10-12 | 2013-01-23 | 中科乐仁(北京)科技发展有限公司 | Health-care food composite with function of assisting in reducing blood fat and preparation method thereof |
CN103462025A (en) * | 2013-09-29 | 2013-12-25 | 厦门中药厂有限公司 | Health food assisting in reducing blood fat and preparation method and application thereof |
CN104432091A (en) * | 2014-11-28 | 2015-03-25 | 江苏天美健大自然生物工程有限公司 | Natto, soybean phospholipid and red yeast rice contained health food with blood sugar reduction function and preparation method of health food |
-
2015
- 2015-09-23 CN CN201510613556.2A patent/CN105310075A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1714675A (en) * | 2005-07-26 | 2006-01-04 | 李英姬 | Natto powder and preparing method and health food containing such natto powder |
CN101664184A (en) * | 2009-09-22 | 2010-03-10 | 黑龙江省祖研北药科技开发有限责任公司 | Healthcare product for reducing blood fat and preparation method thereof |
CN102600227A (en) * | 2012-03-05 | 2012-07-25 | 吴江谷力生物科技有限公司 | Compound functional red rice capsule |
CN102885306A (en) * | 2012-10-12 | 2013-01-23 | 中科乐仁(北京)科技发展有限公司 | Health-care food composite with function of assisting in reducing blood fat and preparation method thereof |
CN103462025A (en) * | 2013-09-29 | 2013-12-25 | 厦门中药厂有限公司 | Health food assisting in reducing blood fat and preparation method and application thereof |
CN104432091A (en) * | 2014-11-28 | 2015-03-25 | 江苏天美健大自然生物工程有限公司 | Natto, soybean phospholipid and red yeast rice contained health food with blood sugar reduction function and preparation method of health food |
Non-Patent Citations (2)
Title |
---|
MACROSZR: "金奥力牌纳豆红曲胶囊", 《百度百科(HTTPS://BAIKE.BAIDU.COM/HISTORY/金奥力牌纳豆红曲胶囊/64876901)》 * |
高学敏等: "《中国药典中药材及饮片彩色图鉴》", 31 March 2015 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105661335A (en) * | 2016-02-25 | 2016-06-15 | 贵州秀生堂医药生物有限公司 | Preparation method of natto enteric capsule functional food |
CN106376926A (en) * | 2016-08-31 | 2017-02-08 | 成都润馨堂药业有限公司 | Formula and preparation method of hard capsule with assisted blood fat reducing function |
CN106616367A (en) * | 2016-09-12 | 2017-05-10 | 福建农林大学 | Method for preparing blood-lipid-reducing vinegar beans through coupling of soybean endogenous enzyme bioconversion and acidolysis |
CN106616284A (en) * | 2016-12-29 | 2017-05-10 | 恩施市大集焦氏米业有限责任公司 | Selenium-enriched nutritious rice flour with auxiliary blood-lipid reducing effect and preparation method thereof |
CN106798252A (en) * | 2017-01-20 | 2017-06-06 | 武汉虹辰远荣生物制品有限公司 | A kind of natto prescription with coordinating intestines and stomach reducing blood lipid thrombus dissolving effect |
CN106954798A (en) * | 2017-03-11 | 2017-07-18 | 北京中科卓尔生物科技有限公司 | Red yeast rice natto fine powder and preparation method thereof |
CN107343605A (en) * | 2017-05-15 | 2017-11-14 | 蚌埠市星光豆制品厂 | A kind of instant natto of flavor |
CN107087739A (en) * | 2017-05-26 | 2017-08-25 | 西宝生物科技(上海)股份有限公司 | Solid beverage formula for improving turbid phlegm and blood stasis |
WO2019024016A1 (en) * | 2017-08-02 | 2019-02-07 | 江苏安惠生物科技有限公司 | Immunity-enhancing capsule |
CN107751801A (en) * | 2017-10-19 | 2018-03-06 | 长沙爱扬医药科技有限公司 | The natto product of prevention of cardiovascular disease |
CN108771248A (en) * | 2018-05-17 | 2018-11-09 | 吉林修正健康股份有限公司 | A kind of health-care food for assisting blood fat lowering full of nutrition and preparation method thereof |
CN108991358A (en) * | 2018-07-24 | 2018-12-14 | 山东海钰生物股份有限公司 | A kind of auxiliary reducing blood lipid, it is hypoglycemic, alleviate gout health care food and production method |
CN109589356A (en) * | 2018-11-29 | 2019-04-09 | 天津市农业生物技术研究中心 | A kind of cassia seed composition with auxiliary lipid-lowering efficacy |
CN109602023A (en) * | 2019-01-21 | 2019-04-12 | 因皇生物科技有限公司 | A kind of functional food and preparation method thereof assisting reducing blood lipid using soybean as primary raw material |
CN110859869A (en) * | 2019-12-20 | 2020-03-06 | 中国中医科学院中医药科技合作中心 | A composition for preventing and treating cardiovascular and cerebrovascular diseases, and its preparation method |
CN111700271A (en) * | 2020-07-02 | 2020-09-25 | 山东花为酶生物科技有限公司 | Preparation method of functional food for regulating blood fat, removing freckles and reducing blood viscosity |
CN112999261A (en) * | 2021-03-22 | 2021-06-22 | 天津市宝恒生物科技有限公司 | Natto fermented composition capable of relieving arteriosclerosis and preparation method and application thereof |
CN115299596A (en) * | 2021-11-10 | 2022-11-08 | 山东安然纳米实业发展有限公司 | Ginseng stem cell-containing composition for assisting in reducing blood fat and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105310075A (en) | Preparation method of natto red yeast rice health care food for assisting in lowering blood lipid | |
CN103099089B (en) | Health-care product for reducing blood sugar and blood pressure, relaxing bowels, losing weight, resisting fatigue and improving sexual function and production technology thereof | |
WO2018010441A1 (en) | Chinese medicine healthcare preparations for slimming and weight loss | |
US9439937B2 (en) | Rat-eye bean extract improving blood glucose control and bioactivity and method of producing the same | |
CN104013698A (en) | Natto crataegus pinnatifida capsule with assistant blood fat reduction function and preparation method thereof | |
KR20110041050A (en) | Composition containing extract of fermentated tea for improving circulation of blood and mitigating cold symptoms in hands and feet | |
CN100444746C (en) | A refined health food of high and cold mountain area crop and processing technology thereof | |
CN105707876B (en) | It is a kind of that there is the dietary composition and its preparation method and application stablized and dissolve patch | |
CN105265985B (en) | A kind of corn stigma solid beverage and preparation method thereof | |
CN106176953A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, Fructus Momordicae and Folium Mori | |
CN104027494B (en) | A kind of Chinese medicine composition with anti-aging and health-care efficacy | |
CN103070333B (en) | Cordyceps militaries (active substance) polysaccharide extraction and capsule preparation method | |
CN102754833B (en) | Healthcare product with function of enhancing immunity and preparation method thereof | |
CN106176952A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja and Folium Ilicis | |
CN102177993A (en) | Stomach-strengthening and digestion-promoting tea and preparation method thereof | |
CN103655697A (en) | Product for reducing blood fat and preparation process thereof | |
CN108066384A (en) | A kind of Chinese medicine preparation with strengthen immunity and preparation method thereof | |
CN106070783A (en) | A kind of production technology of Semen Coicis damp eliminating tea | |
CN102652561A (en) | Vegetable protein food for treating micro-disease or assisting medicament in rehabilitating sick body and production method thereof | |
JP2004352626A (en) | Anticholesterol agent containing plant-derived component | |
CN107969703A (en) | A kind of chu chrysanthemum hypoglycemic breakfast aleuron and preparation method thereof | |
CN106819223A (en) | A kind of health-care milk tea and preparation method thereof | |
CN107158245A (en) | A kind of pharmaceutical formulation and its medicament and preparation method for being used to treat diabetes | |
CN107372947B (en) | Tea bag type blood sugar reducing tea and preparation method thereof | |
CN104474337A (en) | Preparation method of Chinese patent health granule containing green tea extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160210 |
|
RJ01 | Rejection of invention patent application after publication |